According to a Food and Drug Administration post Friday, the FDA's Nonprescription Drugs Advisory Committee will be meeting Nov. 9 regarding the partial switch application from prescription to over the counter of Oxytrol (oxybutynin transdermal system), as submitted by MSD Consumer.
While the growth in healthcare costs remains a threat in the United States, the growth in drug expenditures is moderating, but numerous opportunities exist for retail, according to a speech delivered Tuesday morning at the National Association of Chain Drug Stores' 2012 Pharmacy and Technology Conference in Denver by Doug Long, VP industry relations of healthcare industry research firm IMS Health.
A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.
How can Congress plug the leaks in the pharmaceutical supply chain and dry up the stream of gray market drugs without making the current drug shortage even worse? And can federal regulators shut down gray market profiteers without limiting “the ability of pharmacies to take care of their patients?”
The National Association of Chain Drug Stores announced on Wednesday that it has submitted a statement to the Senate Caucus on International Narcotics Control, detailing chain pharmacy’s engagement in the prevention of prescription drug abuse, and its commitment to maintaining patients’ ready access to medications vital for pain management and for treatment regimens.
Several policy-makers and companies have sought ways to confront the problem of prescription drug abuse. Last month, New York Gov. Andrew Cuomo announced a plan — calling it the first in the country — to create an all- electronic registry that would enable doctors, pharmacists and law enforcement to track controlled substances to prevent excessive prescription and refill requests.
A new continuing-education program offered by a national pharmacist professional organization aims to prepare pharmacists to communicate with patients about the safe and effective use of the painkiller acetaminophen.
The National Association of Chain Drug Stores on Wednesday urged Congress to pass the Prescription Drug User Fee Act, legislation essential to the review process for new medications and that also contains important pro-patient, pro-pharmacy provisions.
In healthcare technology circles, e-prescribing is among today’s hottest topics. A vital component of patient-centered care, it creates a connectivity platform that encourages collaboration between the physician and pharmacist who are in joint pursuit of an enhanced patient experience.
As the U.S. Senate and House reconcile their versions of the Prescription Drug User Fee Act, the National Association of Chain Drug Stores on Wednesday urged U.S. House and Senate leaders to expand provisions in the final bill to help ensure that Americans continue to have access to safe and effective prescription medications, while also curbing prescription drug abuse.
The House Ways and Means Committee on Thursday approved the Restoring Access to Medication Act (H.R. 5842), which would repeal the provision of the Patient Protection and Affordable Care Act that disqualified expenses for over-the-counter drugs as eligible for reimbursement under health savings accounts and flexible spending arrangements without a prescription.
The House of Representatives will vote to repeal limitations on the use of tax-advantaged accounts for the purchase of over-the-counter medications as early as June 4, according to a report published online by The Hill, a Washington, D.C.-based political newspaper.
Following the Senate’s defeat of a proposal that would have permitted “personal importation” of prescription drug medications, the National Association of Chain Drug Stores lauded the Senate’s decision to support patient safety.
Walgreens on Tuesday infused greater value into its Prescription Savings Club program, which now offers discounts on more than 8,000 brand-name and generic prescriptions, thanks to the inclusion of more than 700 "value-priced" generics, which retail as low as $12 for a 90-day supply.